The FDA approved Cobenfy, a new drug for people with schizophrenia that comes with fewer side effects than other ...
The US Food and Drug Administration has approved Cobenfy, which one researcher referred to as a "game changer" for ...
On Thursday, the Food and Drug Administration approved Cobenfy, a drug from Bristol Myers Squibb—the first truly novel ...
The U.S. Food and Drug Administration (FDA) on Thursday approved Bristol Myers Squibb’s (BMY) highly anticipated ...
Available antipsychotic treatments work by blocking dopamine receptors. The new drug, Cobenfy, takes a different approach.
Christopoulos, Dean of the Faculty of Pharmaceutical Sciences at Monash University, is at the centre of a significant ...
The U.S. Food and Drug Administration approved Bristol Myers Squibb's schizophrenia drug late on Thursday, making it the ...
“This drug takes the first new approach to schizophrenia treatment in decades,” Tiffany Farchione ... Cobenfy, set to launch ...
After more than three decades, schizophrenia patients have a new treatment option. The US FDA has approved a drug, known as ...
The twice-daily pill, Cobenfy, is a badly needed new treatment option for the nearly 3 million adults in the U.S. living with ...
Bristol Myers obtained the drug Cobenfy, also known as KarXT, through its $14 billion takeover of Karuna Therapeutics last ...
In three medium-to large-sized clinical trials, Karuna showed that treatment with Cobenfy significantly relieved ...